Regeneron Pharmaceuticals (REGN, Biotechnology) Stock Valuation & Fair Value Favorable on our tests
Regeneron Pharmaceuticals (REGN, Biotechnology) trades at a blended P/E of 14.1, about 38% below its historical normal valuation, with a forward growth estimate of 12.7% and a PEG of 1.11. Analysts' one-year estimates have been hit 55% of the time. Priced at its historical normal P/E of 22.6 on the same blended earnings, the 2026-10-02 close of $735.20 corresponds to about $1,180 a share. This is a valuation reference, not a price target.
- Price $739.57 at the 2026-10-08 close, 3.7% below the 20-day average ($768.21) and 6.3% below the 50-day ($789.29).
- RSI (14) at 38.9.
- 52-week range $554.88 to $852.03: the price is 13.2% below the high and 33.3% above the low.
The Street vs SeerForecast
Wall Street's mean price target for REGN is $853.19 across 26 analysts, 15.4% above the current price. The average analyst rating is Buy. Our SeerForecast read of the same stock, formed without analyst targets: favorable on our tests. When the two disagree, start your digging there.
Valuation flags
- No notable valuation flags.
Verdict history
tickerseer's rating has been favorable on our tests since 2026-06-03.
Not every point was recorded live. Points marked recalculated apply today's valuation rules to the metrics tickerseer archived that week.
Selected weeks: the first, the latest, every week the rating moved, and the cheapest and dearest.
Show all 36 weeks
Frequently asked questions
Is Regeneron Pharmaceuticals stock overvalued?
At a blended P/E of 14.1 versus its historical normal P/E of 22.6, Regeneron Pharmaceuticals trades about 38% below its typical valuation, with a PEG of 1.11 on 12.7% forward growth. tickerseer currently rates it favorable on our tests.
What is Regeneron Pharmaceuticals's fair value and PEG?
Regeneron Pharmaceuticals trades at a blended P/E of 14.1 against a historical normal P/E of 22.6, a PEG of 1.11, and a forward growth estimate of 12.7%. Priced at its historical normal P/E of 22.6 on the same blended earnings, the 2026-10-02 close of $735.20 corresponds to about $1,180 a share. This is a valuation reference, not a price target.
Has tickerseer's rating of Regeneron Pharmaceuticals changed?
tickerseer's rating has been favorable on our tests since 2026-06-03.
What is the analyst price target for Regeneron Pharmaceuticals?
The mean Wall Street price target for Regeneron Pharmaceuticals is $853.19 across 26 analysts, 15.4% above the current price. tickerseer's SeerForecast verdict is formed independently of analyst targets.
Industry: Biotechnology. Create a free account to see the full analysis: the SeerAI score, its five quality sub-scores, valuation history, and the AI research note. Options setups and metric history are part of the paid plans.
Get the free weekly earnings preview
One email each Monday with the week's named earnings setups, the reasoning, and what settled last week. Strikes and sizing stay in Premium.
It's free, and you can unsubscribe any time. We also send a short product update once a month. Educational content, not investment advice.